Xynos Konstantinos
Chief Medical Officer
Xynos Konstantinos has filed 5 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Aug 12, 2026.
On the most recent filing, Xynos Konstantinos is listed as Chief Medical Officer at Replimune Group, Inc. Inside the rolling window, Xynos Konstantinos reported no open-market purchases and 3 open-market sales totaling $286K in REPL. The largest disclosed transaction in the window is a sale of 11,447 REPL shares on Aug 10, 2026, worth $148K.
Companies traded
Other insiders at REPL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$286K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Xynos Konstantinos made?
Xynos Konstantinos has filed 5 SEC Form 4 filings (5 transaction rows) across 1 company since 2025.
Which companies does Xynos Konstantinos trade?
Xynos Konstantinos has filed SEC Form 4 disclosures for 1 company, including REPL.
When was Xynos Konstantinos's most recent SEC Form 4 filing?
Xynos Konstantinos's most recent SEC Form 4 filing on Tracefour is dated Aug 12, 2026.
What is Xynos Konstantinos's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Xynos Konstantinos is listed as Chief Medical Officer.
What is Xynos Konstantinos's total buy and sell value in the current window?
Inside the rolling retention window, Xynos Konstantinos bought $0 and sold $286K based on SEC Form 4 filings.
What was Xynos Konstantinos's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 11,447 REPL shares on 2026-08-10, worth $148K, per SEC Form 4 filings.